Genzyme Corp. (GENZ)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

ONE KENDALL SQ CAMBRIDGE, MA 02139

Genzyme Corporation (Genzyme) is a biotechnology company. The Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune disease. Genzyme operates in four business segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery develops, manufactures and distributes biotherapeutics and biomaterial-based products. Hematologic Oncology develops, manufactures and distributes products for the treatment of cancer.

View SEC Filings from GENZ instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 2 2 0.0% (0.0%) (0.0%)
13F shares: 2 2 0.0%
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls
Total Puts
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding GENZ (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GENZ BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COONEY CHARLES L

  • Director
12,011 2011-12-31 0

SANOFI-AVENTIS

GC MERGER CORP.

  • 10% Owner
253,558,720 2011-04-06 0

MOSCICKI RICHARD A SR VP,CHIEF MEDICAL OFFICER

  • Officer
0 2011-04-04 0

BERTHIAUME DOUGLAS A

  • Director
0 2011-04-04 0

MCGILLICUDY CORNELIUS III

  • Director
0 2011-04-04 0

SMITH SANDFORD D EXE VP,PRESIDENT INT'L GROUP

  • Officer
0 2011-04-04 0

DZAU VICTOR J

  • Director
0 2011-04-04 0

DESROSIER THOMAS SR VP, GENERAL COUNSEL

  • Officer
0 2011-04-04 0

GERAGHTY JAMES A SENIOR VICE PRESIDENT

  • Officer
0 2011-04-04 0

MEEKER DAVID P EXECVP,CHIEF OPERATING OFFICER

  • Officer
0 2011-04-04 0

BOUDREAUX GAIL

  • Director
0 2011-04-04 0

CARPENTER ROBERT J

  • Director
0 2011-04-04 0

SYRON RICHARD F/CA

  • Director
0 2011-04-04 0

CSIMMA ZOLTAN A SRVP,CHIEF HUMAN RESOURCES OFF

  • Officer
0 2011-04-04 0

SMITH ALAN E SR VP,CHIEF SCIENTIFIC OFFICER

  • Officer
0 2011-04-04 0

TERMEER HENRI A CHMN, PRESIDENT AND CEO

  • Officer
  • Director
0 2011-04-04 0

WIRTH PETER EXEC VP,LEGAL & CORPORATE DEV.

  • Officer
0 2011-04-04 0

WYZGA MICHAEL S EXECUTIVE VP AND CFO

  • Officer
0 2011-04-04 0

AMELLO JASON CORPCONTRLLR,CHIEFACCNTOFFICER

  • Officer
0 2011-04-04 0

BERTOLINI ROBERT J

  • Director
0 2011-04-04 0

CANUTE SCOTT A EXECUTIVE VP

  • Officer
0 2011-04-04 0

WHITWORTH RALPH V

  • Director
2,375 2011-04-04 0

BURAKOFF STEVEN

  • Director
0 2011-04-04 0

ENDE ERIC J

  • Director
0 2011-04-04 0

FENTON DENNIS M

  • Director
0 2011-04-04 0

COLLIER EARL M JR EXECUTIVE VICE PRESIDENT

  • Officer
No longer subject to file 2009-12-31 0

BAMFORTH MARK R SR.VP, CORP. OPERATIONS & PHAR

  • Officer
0 2009-05-21 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments